Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned

Abstract

Reports from more than 600 hematopoietic stem cell transplants (HSCT) have appeared in the medical literature for the last 1 and one-half decades. The patient’s own stem cells are harvested and stored temporarily while high doses of chemotherapy and biologics are used to destroy the auto-destructive immune system. The immune system is regenerated from the infused autologous hematopoietic stem cells. Increasing clinical experience has refined patient selection criteria and management in the peri-transplant period leading to a reduction in treatment-related complications. HSCT, when used to treat patients with aggressive highly active multiple sclerosis, can reduce or eliminate ongoing clinical relapses, halt further progression, and reduce the burden of disability in some patients, in the absence of chronic treatment with disease-modifying agents. The top 10 lessons learned from the growing experience using HSCT for the treatment of multiple sclerosis are discussed.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in Multiple sclerosis. Brain 2010;133:1900–1913.

    PubMed  Article  Google Scholar 

  2. 2.

    Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247–256.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Trojano M, Paolicelli D, Tortorella C, et al. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? Neurol Clin 2011;29:309–321.

    PubMed  Article  Google Scholar 

  4. 4.

    Bergamaschi R, Quaglini S, Tavazzi E, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler 2012. doi:10.1177/1352458512445941.

  5. 5.

    Hartung HP, Gonsette R, König N, et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018–2025.

    PubMed  Article  Google Scholar 

  6. 6.

    Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463–1470.

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Karussis DM, Vourka-Karussis U, Lehmann D, et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 1993;92:765–772.

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012;47:770–790.

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Pasquini MC, Voltarelli J, Atkins HL, et al. Transplantation for autoimmune diseases in north and south america: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2012;18:1471–1478.

    PubMed  Article  Google Scholar 

  10. 10.

    Marmont AM. Stem cell transplantation for severe autoimmune diseases: progress and problems. Haematologica 1998;83:733–743.

    PubMed  CAS  Google Scholar 

  11. 11.

    Meloni G, Capria S, Salvetti M, et al. Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia. Haematologica 1999;84:665–667.

    PubMed  CAS  Google Scholar 

  12. 12.

    McAllister LD, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 1997;19:395–397.

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003;102:2364–2372.

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003;102:2373–2378.

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Carreras E, Saiz A, Marín P, et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003;88:306–314.

    PubMed  Google Scholar 

  16. 16.

    Kozák T, Havrdová E, Pit’ha J, et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000;25:525–531.

    PubMed  Article  Google Scholar 

  17. 17.

    Fassas A, Anagnostopoulos A, Kazis A, et al. Autologous stem cell transplantation in progressive multiple sclerosis—an interim analysis of efficacy. J Clin Immunol 2000;20:24–30.

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Saccardi R, Kozak T, Bocelli-Tyndall C, et al. Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006;12:814–823.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Atkins H. Hematopoietic SCT for the treatment of multiple sclerosis. Bone Marrow Transplant 2010;45:1671–1681.

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008;7:626–636.

    PubMed  Article  Google Scholar 

  21. 21.

    Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010;95:284–292.

    PubMed  Article  Google Scholar 

  22. 22.

    Openshaw H, Stuve O, Antel JP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000;54:2147–2150.

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Aboumrad E, Madec AM, Thivolet C. The CXCR4/CXCL12 (SDF-1) signalling pathway protects non-obese diabetic mouse from autoimmune diabetes. Clin Exp Immunol 2007;148:432–439.

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Miljković D, Stanojević Z, Momcilović M, et al. CXCL12 expression within the CNS contributes to the resistance against experimental autoimmune encephalomyelitis in Albino Oxford rats. Immunobiology 2011;216:979–987.

    PubMed  Article  Google Scholar 

  25. 25.

    Zohren F, Toutzaris D, Klärner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008;111:3893–3895.

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008 ;111:3439–3441.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Jing D, Oelschlaegel U, Ordemann R, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010;45:1489–1496.

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Lesesve JF, Debouverie M, Decarvalho Bittencourt M, Béné MC. CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes. Bone Marrow Transplant 2011;46:1489–1491.

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Gress RE, Emerson SG, Drobyski WR. Immune reconstitution: how it should work, what’s broken, and why it matters. Biol Blood Marrow Transplant 2010;16:S133-S137.

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three year of follow up in 21 patients. Clin Transplant 2006;20:485–489.

    PubMed  Article  Google Scholar 

  31. 31.

    Carreras E, Saiz A, Marín P, et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003;88:306–314.

    PubMed  Google Scholar 

  32. 32.

    Su L, Xu J, Ji BX, et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006;84:276–281.

    PubMed  Article  Google Scholar 

  33. 33.

    Atkins H, Freedman M. Immunoablative therapy as a treatment aggressive multiple sclerosis. Neurol Clin 2005;23:273–300.

    PubMed  Article  Google Scholar 

  34. 34.

    van Heeckeren WJ, Vollweiler J, Fu P, et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006;132:42–55.

    PubMed  Article  Google Scholar 

  35. 35.

    Shustov A, Cherian S, Shaw A, et al. In-vivo purging of the circulating clonal T-cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation. Br J Haematol 2011;154:415–418.

    PubMed  Article  Google Scholar 

  36. 36.

    Bahr U, Schulten HR, Hommes OR, Aerts F. Determination of cyclophosphamide in urine, serum and cerebrospinal fluid of multiple sclerosis patients by field desorption mass spectrometry. Clin Chim Acta 1980;103:183–192.

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989;36:525–530.

    PubMed  Article  CAS  Google Scholar 

  38. 38.

    Nash RA, Dansey R, Storek J, et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003;9:583–591.

    PubMed  Article  Google Scholar 

  39. 39.

    Chen JT, Collins DL, Atkins HL, et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006;66:1935–1937.

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol 2009;24:689–698.

    PubMed  Article  Google Scholar 

  41. 41.

    Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol 2011;29:2397–2404.

    PubMed  Article  Google Scholar 

  42. 42.

    Openshaw H, Lund BT, Kashyap A, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulphan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000;6:563–575.

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol 1998;16:3796–3802.

    PubMed  CAS  Google Scholar 

  44. 44.

    Chamberlain MC. Neurotoxicity of cancer treatment. Curr Oncol Rep 2010;12:60–67.

    PubMed  Article  Google Scholar 

  45. 45.

    Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler 2011;17:204–213.

    PubMed  Article  Google Scholar 

  46. 46.

    Mancardi GL, Murialdo A, Rossi P, et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler 2005;11:367–371.

    PubMed  Article  Google Scholar 

  47. 47.

    Kimiskidis V, Sakellari I, Tsimourtou V, et al. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Mult Scler 2008;14:278–283.

    PubMed  Article  CAS  Google Scholar 

  48. 48.

    Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009;15:229–237.

    PubMed  Article  CAS  Google Scholar 

  49. 49.

    Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009;8:244–253.

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Krasulová E, Trneny M, Kozák T, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 2010;16:685–693.

    PubMed  Article  Google Scholar 

  51. 51.

    Mancardi GL, Sormani MP, Di Gioia M, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 2012;18:835–842.

    PubMed  Article  CAS  Google Scholar 

  52. 52.

    Fassas A, Kimiskidis VK, Sakellari I, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 2011;76:1066–1070.

    PubMed  Article  CAS  Google Scholar 

  53. 53.

    Saccardi R, Mancardi GL, Solari A, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005;105:2601–2607.

    PubMed  Article  CAS  Google Scholar 

  54. 54.

    Bowen JD, Kraft GH, Wundes A, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant 2012;47:946–951.

    PubMed  Article  CAS  Google Scholar 

  55. 55.

    Pasquini MC, Griffith LM, Arnold DL, et al. Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant 2010;16:1076–1083.

    PubMed  Article  Google Scholar 

  56. 56.

    Muraro P. Long-term outcomes after autologous HCT for severe multiple sclerosis. In: Center for International Blood and Marrow Transplant Research. Available at: www.cibmtr.org/Studies/Observational/StudyLists/pages/ObservationalStudy.aspx?OSID=34. Accessed August 5, 2012.

  57. 57.

    Saccardi R, Freedman MS, Sormani MP, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler 2012;18:825–834.

    PubMed  Article  CAS  Google Scholar 

  58. 58.

    Shevchenko JL, Kuznetsov AN, Ionova TI, et al. Autologous haematopoietic stem cell transplantation with reduced intensity conditioning in multiple sclerosis. Exp Hematol 2012;40:892–898.

    PubMed  Article  Google Scholar 

  59. 59.

    Chen B, Zhou M, Ouyang J, et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci 2012;33:881–886.

    PubMed  Article  Google Scholar 

  60. 60.

    Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect 2011;17:1776–1780.

    PubMed  Article  CAS  Google Scholar 

  61. 61.

    Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870–1880.

    PubMed  Article  CAS  Google Scholar 

  62. 62.

    Daikeler T, Labopin M, Di Gioia M, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 2011;118:1693–1698.

    PubMed  Article  CAS  Google Scholar 

  63. 63.

    Loh Y, Oyama Y, Statkute L, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007;109:2643–2548.

    PubMed  Article  CAS  Google Scholar 

  64. 64.

    Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011;118:6299–6305.

    PubMed  Article  CAS  Google Scholar 

  65. 65.

    Tappenden P, Saccardi R, Confavreux C, et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant 2010;45:1014–1021.

    PubMed  Article  CAS  Google Scholar 

  66. 66.

    O’Day K, Meyer K, Miller RM, Agarwal S, Franklin M. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011;14:617–627.

    PubMed  Article  Google Scholar 

  67. 67.

    Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543–555.

    PubMed  Google Scholar 

  68. 68.

    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. J Med Econ 2012;15:1088–1096.

    Google Scholar 

  69. 69.

    Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011;77:355–363.

    PubMed  Article  CAS  Google Scholar 

  70. 70.

    Peng F, Qiu W, Li J, et al. A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation. Neurologist 2010;16:375–378.

    PubMed  Article  Google Scholar 

  71. 71.

    Xu J, Ji BX, Su L, et al. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Ann Hematol 2011;90:343–348.

    PubMed  Article  Google Scholar 

Download references

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Harold L. Atkins.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 492 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Atkins, H.L., Freedman, M.S. Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned. Neurotherapeutics 10, 68–76 (2013). https://doi.org/10.1007/s13311-012-0162-5

Download citation

Keywords

  • Hematopoietic stem cell transplantation
  • Multiple sclerosis
  • Autoimmunity
  • Immune ablation